IntelGenX
Our business strategy is to apply our proprietary drug delivery technologies to improve existing drug compounds with proven efficacy and.
Launch date
Employees
Market cap
€26.5m
Enterprise valuation
€41m (Public information from Sep 2024)
Share price
$0.17 IGXT
Montreal Quebec (HQ)
Financials
Estimates*
| USD | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Revenues | 1.7m | <1m | 1.5m | 1.5m | <1m | 1.0m | 30.9m |
| % growth | (65 %) | (57 %) | 108 % | (1 %) | (38 %) | 9 % | 2872 % |
| EBITDA | (7.9m) | (8.7m) | (5.1m) | (7.0m) | (8.6m) | (8.7m) | - |
| % EBITDA margin | (453 %) | (1177 %) | (331 %) | (459 %) | (909 %) | (836 %) | - |
| Profit | (9.6m) | (10.7m) | (7.0m) | (9.3m) | (10.7m) | (9.9m) | - |
| % profit margin | (554 %) | (1437 %) | (456 %) | (607 %) | (1125 %) | (955 %) | - |
| EV / revenue | 27.4x | 68.5x | 20.7x | 36.9x | 44.7x | 35.9x | - |
| EV / EBITDA | -6.0x | -5.8x | -6.3x | -8.0x | -4.9x | -4.3x | - |
| R&D budget | 4.9m | 3.8m | 2.6m | 2.7m | 3.0m | 3.3m | - |
| R&D % of revenue | 280 % | 509 % | 171 % | 177 % | 319 % | 315 % | - |
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | N/A | IPO | |
| N/A | $1.7m | Post IPO Equity | |
| N/A | CAD6.8m | Post IPO Debt | |
| N/A | $3.2m | Post IPO Equity | |
$2.0m | Post IPO Debt | ||
$3.0m | Post IPO Debt | ||
* | $3.0m | Post IPO Debt | |
* | N/A | $760k | Post IPO Convertible |
* | CAD3.0m | Post IPO Equity | |
| Total Funding | - | ||
Recent News about IntelGenX
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.